BMS Reports the EMA’s Validation of Application for Opdivo Plus Yervoy to Treat Hepatocellular Carcinoma
Shots:
- The EMA has validated the Type II variation application of Opdivo + Yervoy as a 1L treatment of unresectable or advanced hepatocellular carcinoma (HCC), not administered with previous systemic therapy
- The application is based on P-III (CheckMate -9DW) study assessing Opdivo (1mg/kg, Q3W) + Yervoy (3mg/kg, Q3W) followed by Opdivo alone (480mg) for 2yrs. vs investigator’s choice of lenvatinib or sorafenib alone to treat unresectable or advanced HCC patients (n=668)
- The study showed improved OS and a manageable safety profile that aligned with previous outcomes without any new concerns. Data was highlighted at ASCO 2024
Ref: BMS | Image: BMS
Related News:- BMS Features the P-III (CheckMate -9DW) Trial Data of Opdivo Plus Yervoy for Treating Advanced Hepatocellular Carcinoma at ASCO 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
